IDEXX LABORATORIES INC /DE (IDXX): Results of Operations and Financial Condition
IDEXX LABORATORIES INC /DE (IDXX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622041d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results ▪ Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ▪ Strong vol
How this was made
The 30-second read
Why it matters
Traders can update models using the narrowed revenue range, raised EPS range, and the stated drivers: CAG Diagnostics recurring revenue performance, operating margin expansion, and FX headwinds.
Market read
The filing provides fresh, quantified guidance changes for 2026 (revenue, organic growth, operating margin, EPS) tied to recurring diagnostics momentum.
What to watch
CAG Diagnostics capital instrument revenues declined 19% reported and 20% organic, which could cap near-term instrument-related growth even as recurring revenue accelerates.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering IDEXX’s Q2 2026 results and updated full-year 2026 guidance.
Ticker impact
IDEXX reported Q2 2026 revenue growth of 10% and EPS of $4.27, and narrowed 2026 revenue guidance to $4,700-$4,745M.
Likely positive near-term bias as traders reprice 2026 growth and margin trajectory; watch for FX headwind sensitivity.
The filing provides specific, updated full-year ranges (revenue, organic growth, operating margin, EPS) and ties them to CAG Diagnostics recurring performance and operating margin expansion.
Market effects
Supports the view that veterinary diagnostics and recurring consumables/software are sustaining mid-to-high single digit organic growth with margin expansion.
International CAG Diagnostics recurring revenue growth is cited as 14% reported and 12% organic, implying strength beyond the U.S.
FX is explicitly called out as a $15M headwind to revenue, highlighting currency sensitivity for global investors.
Counterpoint
The guidance update is modest at the midpoint and includes a stated FX headwind, so upside may be partially accounting-driven rather than purely operational.
Key entities
- companyIDEXX Laboratories, Inc.
Pet healthcare and diagnostics company reporting Q2 2026 results and updating 2026 revenue and EPS guidance.
- business_segmentCAG Diagnostics
Companion Animal Group diagnostics recurring revenue stream cited as the main driver of growth and guidance changes.
- product_platformIDEXX inVue Dx
Installed base and placements are highlighted as supporting recurring diagnostics utilization.